In our exploration of GFPT2’s mechanistic influence on the reaction of ovarian cancer cells to paclitaxel, we discovered a pivotal connection between GFPT2 expression and the NF-κB signaling pathway, which was reported to be a central modulator in cells’ responses to chemotherapeutic agents [7]. Here, NFKB1 is linked to ovarian cancer.